Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Gets Price Target Cut from UBS Group

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price objective lowered by UBS Group from $33.00 to $31.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group‘s price objective suggests a potential upside of 242.92% from the company’s current price.

A number of other equities research analysts have also recently commented on SNDX. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. Bank of America reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. JPMorgan Chase & Co. dropped their price target on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. HC Wainwright lowered their target price on Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. Finally, Weiss Ratings raised shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $41.40.

Read Our Latest Stock Analysis on Syndax Pharmaceuticals

Syndax Pharmaceuticals Price Performance

SNDX traded down $0.09 during midday trading on Friday, hitting $9.04. 888,200 shares of the company traded hands, compared to its average volume of 1,884,865. Syndax Pharmaceuticals has a 52-week low of $8.41 and a 52-week high of $25.59. The company has a current ratio of 4.69, a quick ratio of 4.37 and a debt-to-equity ratio of 38.95. The business has a 50 day simple moving average of $14.41 and a two-hundred day simple moving average of $19.50. The company has a market capitalization of $813.85 million, a price-to-earnings ratio of -3.83 and a beta of 0.48.

Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.05). Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 804.38%. The company had revenue of $83.30 million during the quarter, compared to analyst estimates of $81.38 million. During the same quarter last year, the business posted ($0.70) EPS. The firm’s revenue for the quarter was up 81.9% on a year-over-year basis. On average, equities analysts forecast that Syndax Pharmaceuticals will post -2.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $14.21, for a total transaction of $113,680.00. Following the sale, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. This represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in SNDX. Algert Global LLC boosted its stake in shares of Syndax Pharmaceuticals by 5.9% in the 3rd quarter. Algert Global LLC now owns 1,113,607 shares of the company’s stock valued at $20,936,000 after purchasing an additional 62,142 shares in the last quarter. Jump Financial LLC grew its position in shares of Syndax Pharmaceuticals by 31.7% during the 3rd quarter. Jump Financial LLC now owns 530,466 shares of the company’s stock worth $9,973,000 after buying an additional 127,620 shares during the period. Apis Capital Advisors LLC lifted its holdings in shares of Syndax Pharmaceuticals by 8.8% in the 3rd quarter. Apis Capital Advisors LLC now owns 605,000 shares of the company’s stock worth $11,374,000 after purchasing an additional 49,000 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter worth about $368,000. Finally, Bleakley Financial Group LLC purchased a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $299,000.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.

Further Reading

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.